AWM
SAGE

Activest Wealth Management’s Sage Therapeutics SAGE Stock Holding History

Activest Wealth Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1
Closed -$9 – 1191
2025
Q2 		$9 Hold
1
– – ﹤0.01% 1023
2025
Q1 		$8 Hold
1
– – ﹤0.01% 1031
2024
Q4 		$5 Hold
1
– – ﹤0.01% 890
2024
Q3 		$7 Hold
1
– – ﹤0.01% 557
2024
Q2 		$11 Buy
+1
New +$13 ﹤0.01% 515

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Activest Wealth Management's SAGE Position: Q3 2025 in Review

Activest Wealth Management sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 1 share — an estimated $9 sold.

Activest Wealth Management first reported a position in SAGE in Q2 2024 and held it in 5 quarters. The position peaked at $11 in Q2 2024. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • Activest Wealth Management reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Activest Wealth Management sold 1 Sage Therapeutics share in Q3 2025, an estimated $9.
  • Activest Wealth Management first reported a position in Sage Therapeutics in Q2 2024 and held it in 5 quarters.
  • Activest Wealth Management's Sage Therapeutics position peaked at $11 in Q2 2024.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Activest Wealth Management's 13F filing for Q3 2025, filed 3 Nov 2025.